78 MARINE INGREDIENTS
Promoting bacterial balance The study demonstrated that both of the Maritech fucoidan extracts inhibited the adhesion of bacteria typically associated with inflammatory skin conditions. Both extracts had no effect on the bacteria commonly associated with good skin health.
Inhibiting Staphylococcus aureus The predominant symptom of the inflammatory disease AD is itchy
skin.As patients scratch their skin in an attempt to find relief, disruption of the epidermal barrier commonly occurs. This provides opportunity for increased colonisation of Staphylococcus aureus, a bacterium typically abundant in the skin of AD patients. Many AD patients suffer from recurrent skin infections and are susceptible to the colonisation of apparently healthy skin by S. aureus.5
This
opportunistic pathogen is commonly thought to exacerbate this widespread and debilitating dermatological condition. The study showed that fucoidan significantly
inhibited the adhesion of S. aureus on reconstructed human epidermis (Figure 1). Inhibiting Cutibacterium acnes Cutibacterium acnes is believed to play an important role in the common skin disease acne vulgaris.6
This inflammation can lead Figure 2: Concentrations of adherent C. acnes after topical treatment with Maritech fucoidan Whilst common within the pores
and follicles of healthy skin, the multiplication of C. acnes can result in inflammation and the destabilisation of the cell walls within skin follicles.7
to common skin disorders such as acne – a condition which affects almost 10% of the global population.8 The study showed that both Maritech
fucoidan ingredients significantly inhibited the adhesion of C. acnes (Figure 2).
Maintaining Staphylococcus epidermidis Staphylococcus epidermidis is a common bacterium found on healthy skin. Extensive research has been applied to S. epidermidis and its role as a beneficial skin commensal, including investigations into the modulation of immune response to skin infection.9,10 Recent studies have indicated that an
important relationship exists between C. acnes and the bacterium Staphylococcus epidermidis as S. epidermidis can limit the over colonisation of C. acnes.11
This new study
showed that Maritech fucoidan did not affect the adhesion of Staphylococcus epidermidis (Figure 3).The inhibition of C. acnes and the preservation of S. epidermidis is therefore of significant interest for future therapeutic treatments targeting acne.
Atopic dermatitis and gene expression To gain a greater understanding of whether topical fucoidan could potentially alter gene expression, further analysis was carried out in an in vitro 3D model of AD. The study showed that fucoidan
significantly altered gene expression. Genes that were beneficially affected included those typically associated with skin barrier function, wound healing processes and fluid accumulation.
PERSONAL CARE November 2021
Reducing periostin Interestingly, the study also showed a subtle inhibition of the release of the protein periostin. Periostin tends to be highly expressed in chronic inflammatory diseases and is a well-known marker of AD.3 A microbiome future The human skin is a complex physiological barrier designed to protect the body from biological, chemical and physical harm. Natural ingredients supported by scientific evidence, such as bioactive algal compounds, are becoming increasingly attractive to protect and restore skin health.13
In addition to its demonstrated soothing,
brightening, antioxidant and protecting properties, the ability of Maritech fucoidan to potentially support a healthy epidermal barrier and assist in the balancing of skin microbiome looks increasingly promising.4 This latest research paves the way for further
skin microbiome research utilising topical fucoidan compounds. A deeper understanding of the potential of fucoidan to regulate skin microbiome is applicable not only to the beauty market, but also for use in dermatology to address widespread and debilitating skin diseases.
Serious about sustainability Maritech organic fucoidan extracts are derived from wild seaweeds grown in pristine ocean waters. Harvesting of this rapidly renewable marine resource is conducted in accordance with world’s best practice. Marinova hand- harvests seaweed on an environmentally sustainable basis and does not source seaweed that is farmed or from any parts of the world prone to human, industrial or agricultural contamination, or where sustainable harvesting practices cannot be guaranteed. The proprietary Maritech extraction process utilises unique green chemistry principles to produce superior quality compounds. The Maritech process does not involve the use of solvents or other environmentally harmful chemicals. It is by virtue of this unique technology that Maritech organic fucoidan is the world’s only high purity, certified organic fucoidan with global regulatory acceptance. All seaweed residues are diverted into
new, value-added products. Both liquid and solid by-products of the Maritech process are converted into nutrient-rich additives for the horticultural sector. The commitment to efficient manufacturing processes is further evidenced by the entire production process being powered by renewable energy.
Formulation & safety Clinical and in vitro testing has confirmed the bioactivity of Maritech Bright and Maritech Reverse at 0.1-0.3% w/v. Both ingredients are water-soluble and are readily included in gels, creams and serums. They are simple to store - a cool dry place in well-sealed containers that are protected from light, heat and moisture - and are shelf-stable for five years. All Maritech fucoidan extracts are
certified organic and have global regulatory acceptance. They are produced in Australia in ISO9001-, HACCP- and GMP-accredited facilities. Extensive clinical testing has confirmed that both Maritech Bright and Maritech Reverse are safe for topical application. They are free from preservatives, non-sensitising, non-irritating, non-allergenic and have never been tested on animals.
6.0 x 104
4.0 x 104
2.0 x 104
0 Control Maritech Bright Maritech Reverse
PC
www.personalcaremagazine.com
Adherent cells (CFU/RHE)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104
